Correction to: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (npj Breast Cancer, (2022), 8, 1, (98), 10.1038/s41523-022-00467-1)
- Rugo, H.S.
- Tolaney, S.M.
- Loirat, D.
- Punie, K.
- Bardia, A.
- Hurvitz, S.A.
- O’Shaughnessy, J.
- Cortés, J.
- Diéras, V.
- Carey, L.A.
- Gianni, L.
- Piccart, M.J.
- Loibl, S.
- Goldenberg, D.M.
- Hong, Q.
- Olivo, M.
- Itri, L.M.
- Kalinsky, K.
Revista:
npj Breast Cancer
ISSN: 2374-4677
Any de publicació: 2024
Volum: 10
Número: 1
Tipus: Errata